Which has higher valuation and earnings, IMUX or RADX?

Radiopharm Theranostics has higher revenue and earnings than Immunic. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunic N/A N/A -$97.17M -$5.58 N/A Radiopharm Theranostics $2.35M 21.56 -$24.83M N/A N/A

Is IMUX or RADX more profitable?

Radiopharm Theranostics' return on equity of 0.00% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Immunic N/A -220.75% -132.04% Radiopharm Theranostics N/A N/A N/A

Which has higher earnings and valuation, ABOS or RADX?

Radiopharm Theranostics has higher revenue and earnings than Acumen Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acumen Pharmaceuticals N/A N/A -$121.33M -$1.86 N/A Radiopharm Theranostics $2.35M 21.56 -$24.83M N/A N/A

Is ABOS or RADX more profitable?

Radiopharm Theranostics' return on equity of 0.00% beat Acumen Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Acumen Pharmaceuticals N/A -123.07% -79.41% Radiopharm Theranostics N/A N/A N/A

Does the media refer more to ABOS or RADX?

In the previous week, Acumen Pharmaceuticals had 3 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 4 mentions for Acumen Pharmaceuticals and 1 mentions for Radiopharm Theranostics. Acumen Pharmaceuticals' average media sentiment score of 0.33 beat Radiopharm Theranostics' score of 0.00 indicating that Acumen Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acumen Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Radiopharm Theranostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, RADX or CRBU?

Radiopharm Theranostics has higher earnings, but lower revenue than Caribou Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Radiopharm Theranostics $2.35M 21.56 -$24.83M N/A N/A Caribou Biosciences $11.16M 14.66 -$148.12M -$1.42 N/A

Which has preferable valuation & earnings, EQ or RADX?

Equillium has higher revenue and earnings than Radiopharm Theranostics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Equillium $41.10M 4.05 -$22.40M -$0.32 N/A Radiopharm Theranostics $2.35M 21.56 -$24.83M N/A N/A

Is EQ or RADX more profitable?

Radiopharm Theranostics' return on equity of 0.00% beat Equillium's return on equity. Company Net Margins Return on Equity Return on Assets Equillium N/A -61.43% -53.72% Radiopharm Theranostics N/A N/A N/A

Does the media prefer EQ or RADX?

In the previous week, Equillium had 3 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 4 mentions for Equillium and 1 mentions for Radiopharm Theranostics. Equillium's average media sentiment score of 0.25 beat Radiopharm Theranostics' score of 0.00 indicating that Equillium is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Equillium 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Radiopharm Theranostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, ACOG or RADX?

Alpha Cognition has higher revenue and earnings than Radiopharm Theranostics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alpha Cognition $10.22M 16.81 -$20.67M -$1.35 N/A Radiopharm Theranostics $2.35M 21.56 -$24.83M N/A N/A

Does the media prefer ACOG or RADX?

In the previous week, Alpha Cognition and Alpha Cognition both had 1 articles in the media. Alpha Cognition's average media sentiment score of 0.00 equaled Radiopharm Theranostics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alpha Cognition 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Radiopharm Theranostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Radiopharm Theranostics (RADX) Competitors

$4.29 +0.01 (+0.23%)

Closing price 04:00 PM Eastern

Extended Trading

$4.38 +0.09 (+1.98%)

As of 07:55 PM Eastern

Compare

RADX vs. IMUX, ABOS, CRBU, EQ, and ACOG

Should you buy Radiopharm Theranostics stock or one of its competitors? MarketBeat compares Radiopharm Theranostics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Radiopharm Theranostics include Immunic (IMUX), Acumen Pharmaceuticals (ABOS), Caribou Biosciences (CRBU), Equillium (EQ), and Alpha Cognition (ACOG). These companies are all part of the "med - biomed/gene" industry.

How does Radiopharm Theranostics compare to Immunic?

Immunic (NASDAQ:IMUX) and Radiopharm Theranostics (NASDAQ:RADX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, media sentiment, profitability, valuation and institutional ownership.

Radiopharm Theranostics' return on equity of 0.00% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-220.75%	-132.04%
Radiopharm Theranostics	N/A	N/A	N/A

In the previous week, Radiopharm Theranostics had 1 more articles in the media than Immunic. MarketBeat recorded 1 mentions for Radiopharm Theranostics and 0 mentions for Immunic. Immunic's average media sentiment score of 0.00 equaled Radiopharm Theranostics'average media sentiment score.

Company	Overall Sentiment
Immunic	Neutral
Radiopharm Theranostics	Neutral

51.8% of Immunic shares are held by institutional investors. 5.5% of Immunic shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Immunic presently has a consensus target price of $47.57, indicating a potential upside of 214.00%. Radiopharm Theranostics has a consensus target price of $11.00, indicating a potential upside of 156.41%. Given Immunic's stronger consensus rating and higher possible upside, analysts plainly believe Immunic is more favorable than Radiopharm Theranostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Immunic has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market. Comparatively, Radiopharm Theranostics has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market.

Radiopharm Theranostics has higher revenue and earnings than Immunic.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A
Radiopharm Theranostics	$2.35M	21.56	-$24.83M	N/A	N/A

Summary

Immunic and Radiopharm Theranostics tied by winning 6 of the 12 factors compared between the two stocks.

How does Radiopharm Theranostics compare to Acumen Pharmaceuticals?

Acumen Pharmaceuticals (NASDAQ:ABOS) and Radiopharm Theranostics (NASDAQ:RADX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

Radiopharm Theranostics has higher revenue and earnings than Acumen Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.86	N/A
Radiopharm Theranostics	$2.35M	21.56	-$24.83M	N/A	N/A

Acumen Pharmaceuticals has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market. Comparatively, Radiopharm Theranostics has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market.

Acumen Pharmaceuticals currently has a consensus price target of $8.00, suggesting a potential upside of 258.74%. Radiopharm Theranostics has a consensus price target of $11.00, suggesting a potential upside of 156.41%. Given Acumen Pharmaceuticals' higher possible upside, research analysts plainly believe Acumen Pharmaceuticals is more favorable than Radiopharm Theranostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

71.0% of Acumen Pharmaceuticals shares are held by institutional investors. 10.2% of Acumen Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Radiopharm Theranostics' return on equity of 0.00% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%
Radiopharm Theranostics	N/A	N/A	N/A

In the previous week, Acumen Pharmaceuticals had 3 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 4 mentions for Acumen Pharmaceuticals and 1 mentions for Radiopharm Theranostics. Acumen Pharmaceuticals' average media sentiment score of 0.33 beat Radiopharm Theranostics' score of 0.00 indicating that Acumen Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acumen Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Radiopharm Theranostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Acumen Pharmaceuticals and Radiopharm Theranostics tied by winning 5 of the 10 factors compared between the two stocks.

How does Radiopharm Theranostics compare to Caribou Biosciences?

Radiopharm Theranostics (NASDAQ:RADX) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

Radiopharm Theranostics has a net margin of 0.00% compared to Caribou Biosciences' net margin of -1,189.14%. Radiopharm Theranostics' return on equity of 0.00% beat Caribou Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Radiopharm Theranostics	N/A	N/A	N/A
Caribou Biosciences	-1,189.14%	-84.17%	-60.51%

77.5% of Caribou Biosciences shares are held by institutional investors. 8.5% of Caribou Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Radiopharm Theranostics had 1 more articles in the media than Caribou Biosciences. MarketBeat recorded 1 mentions for Radiopharm Theranostics and 0 mentions for Caribou Biosciences. Radiopharm Theranostics' average media sentiment score of 0.00 equaled Caribou Biosciences'average media sentiment score.

Company	Overall Sentiment
Radiopharm Theranostics	Neutral
Caribou Biosciences	Neutral

Radiopharm Theranostics has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market. Comparatively, Caribou Biosciences has a beta of 2.36, indicating that its share price is 136% more volatile than the broader market.

Radiopharm Theranostics currently has a consensus target price of $11.00, indicating a potential upside of 156.41%. Caribou Biosciences has a consensus target price of $8.67, indicating a potential upside of 425.25%. Given Caribou Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Caribou Biosciences is more favorable than Radiopharm Theranostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Caribou Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Radiopharm Theranostics has higher earnings, but lower revenue than Caribou Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Radiopharm Theranostics	$2.35M	21.56	-$24.83M	N/A	N/A
Caribou Biosciences	$11.16M	14.66	-$148.12M	-$1.42	N/A

Summary

Caribou Biosciences beats Radiopharm Theranostics on 7 of the 13 factors compared between the two stocks.

How does Radiopharm Theranostics compare to Equillium?

Equillium (NASDAQ:EQ) and Radiopharm Theranostics (NASDAQ:RADX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings.

Equillium has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market. Comparatively, Radiopharm Theranostics has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market.

Equillium has higher revenue and earnings than Radiopharm Theranostics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Equillium	$41.10M	4.05	-$22.40M	-$0.32	N/A
Radiopharm Theranostics	$2.35M	21.56	-$24.83M	N/A	N/A

27.1% of Equillium shares are owned by institutional investors. 17.8% of Equillium shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Equillium presently has a consensus price target of $7.57, suggesting a potential upside of 187.89%. Radiopharm Theranostics has a consensus price target of $11.00, suggesting a potential upside of 156.41%. Given Equillium's stronger consensus rating and higher probable upside, research analysts plainly believe Equillium is more favorable than Radiopharm Theranostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Equillium	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.70
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Radiopharm Theranostics' return on equity of 0.00% beat Equillium's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Equillium	N/A	-61.43%	-53.72%
Radiopharm Theranostics	N/A	N/A	N/A

In the previous week, Equillium had 3 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 4 mentions for Equillium and 1 mentions for Radiopharm Theranostics. Equillium's average media sentiment score of 0.25 beat Radiopharm Theranostics' score of 0.00 indicating that Equillium is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Equillium	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Radiopharm Theranostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Equillium beats Radiopharm Theranostics on 11 of the 14 factors compared between the two stocks.

How does Radiopharm Theranostics compare to Alpha Cognition?

Alpha Cognition (NASDAQ:ACOG) and Radiopharm Theranostics (NASDAQ:RADX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

Alpha Cognition presently has a consensus price target of $16.00, indicating a potential upside of 102.79%. Radiopharm Theranostics has a consensus price target of $11.00, indicating a potential upside of 156.41%. Given Radiopharm Theranostics' higher possible upside, analysts clearly believe Radiopharm Theranostics is more favorable than Alpha Cognition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Alpha Cognition has a beta of 2.32, meaning that its share price is 132% more volatile than the broader market. Comparatively, Radiopharm Theranostics has a beta of 1.41, meaning that its share price is 41% more volatile than the broader market.

Alpha Cognition has higher revenue and earnings than Radiopharm Theranostics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Cognition	$10.22M	16.81	-$20.67M	-$1.35	N/A
Radiopharm Theranostics	$2.35M	21.56	-$24.83M	N/A	N/A

In the previous week, Alpha Cognition and Alpha Cognition both had 1 articles in the media. Alpha Cognition's average media sentiment score of 0.00 equaled Radiopharm Theranostics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Cognition	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Radiopharm Theranostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Radiopharm Theranostics has a net margin of 0.00% compared to Alpha Cognition's net margin of -232.23%. Radiopharm Theranostics' return on equity of 0.00% beat Alpha Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	-232.23%	-58.35%	-45.99%
Radiopharm Theranostics	N/A	N/A	N/A

Summary

Alpha Cognition and Radiopharm Theranostics tied by winning 5 of the 10 factors compared between the two stocks.

Get Radiopharm Theranostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RADX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RADX vs. The Competition

Export

Metric	Radiopharm Theranostics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$50.56M	$3.63B	$6.81B	$12.32B
Dividend Yield	N/A	2.19%	2.67%	9.67%
P/E Ratio	N/A	20.62	26.97	24.18
Price / Sales	21.56	306.37	518.41	96.05
Price / Cash	N/A	150.24	49.71	59.37
Price / Book	1.22	8.17	10.67	6.25
Net Income	-$24.83M	$23.81M	$3.60B	$331.66M
7 Day Performance	-0.23%	-1.16%	-0.37%	-1.10%
1 Month Performance	-3.60%	2.59%	1.80%	-1.29%
1 Year Performance	-0.46%	45.43%	25.50%	18.84%

Radiopharm Theranostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RADX Radiopharm Theranostics	2.5905 of 5 stars	$4.29 +0.2%	$11.00 +156.4%	-3.4%	$50.56M	$2.35M	N/A	N/A
IMUX Immunic	2.6702 of 5 stars	$14.77 -0.1%	$47.57 +222.1%	+55.6%	$201.33M	N/A	N/A	70
ABOS Acumen Pharmaceuticals	2.453 of 5 stars	$2.63 -2.6%	$8.00 +204.2%	+47.3%	$195.01M	N/A	N/A	20
CRBU Caribou Biosciences	1.7211 of 5 stars	$1.93 -0.8%	$8.67 +350.2%	-21.0%	$192.41M	$11.16M	N/A	100
EQ Equillium	2.7386 of 5 stars	$2.91 -1.7%	$7.57 +160.2%	+495.0%	$187.15M	$41.10M	N/A	40	News Coverage High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RADX) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Radiopharm Theranostics (RADX) Competitors

RADX vs. IMUX, ABOS, CRBU, EQ, and ACOG

How does Radiopharm Theranostics compare to Immunic?

Summary

How does Radiopharm Theranostics compare to Acumen Pharmaceuticals?

Summary

How does Radiopharm Theranostics compare to Caribou Biosciences?

Summary

How does Radiopharm Theranostics compare to Equillium?

Summary

How does Radiopharm Theranostics compare to Alpha Cognition?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RADX vs. The Competition

Radiopharm Theranostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Radiopharm Theranostics (RADX) Competitors

RADX vs. IMUX, ABOS, CRBU, EQ, and ACOG

How does Radiopharm Theranostics compare to Immunic?

Is IMUX or RADX more profitable?

Does the media refer more to IMUX or RADX?

Do institutionals & insiders have more ownership in IMUX or RADX?

Do analysts recommend IMUX or RADX?

Which has more volatility & risk, IMUX or RADX?

Which has higher valuation and earnings, IMUX or RADX?

Summary

How does Radiopharm Theranostics compare to Acumen Pharmaceuticals?

Which has higher earnings and valuation, ABOS or RADX?

Which has more risk & volatility, ABOS or RADX?

Do analysts prefer ABOS or RADX?

Do insiders & institutionals hold more shares of ABOS or RADX?

Is ABOS or RADX more profitable?

Does the media refer more to ABOS or RADX?

Summary

How does Radiopharm Theranostics compare to Caribou Biosciences?

Is RADX or CRBU more profitable?

Do insiders and institutionals have more ownership in RADX or CRBU?

Does the media prefer RADX or CRBU?

Which has more risk & volatility, RADX or CRBU?

Do analysts recommend RADX or CRBU?

Which has better valuation & earnings, RADX or CRBU?

Summary

How does Radiopharm Theranostics compare to Equillium?

Which has more risk & volatility, EQ or RADX?

Which has preferable valuation & earnings, EQ or RADX?

Do insiders and institutionals hold more shares of EQ or RADX?

Do analysts recommend EQ or RADX?

Is EQ or RADX more profitable?

Does the media prefer EQ or RADX?

Summary

How does Radiopharm Theranostics compare to Alpha Cognition?

Do analysts recommend ACOG or RADX?

Which has more risk and volatility, ACOG or RADX?

Which has higher earnings and valuation, ACOG or RADX?

Does the media prefer ACOG or RADX?

Is ACOG or RADX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RADX vs. The Competition

Radiopharm Theranostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools